Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

RaysightMed Secures Nearly RMB 100 Million in Strategic Financing Led by State-Owned Capital – Accelerates Cardiovascular Diagnostics Scale-Up and AI Surgical Robotics Development

Fineline Cube Jul 1, 2026
Company Deals

Ribo Life Science Acquires Additional 25.93% Stake in Azemidite for RMB 70 Million – Strengthens siRNA Therapeutics Supply Chain

Fineline Cube Jul 1, 2026
Company Deals

METiS TechBio Signs Record $1.62B Global Licensing Deal for AI-Designed Tri-Specific TCE MTS-128 – Largest Preclinical TCE Out-Licensing by Chinese Pharma Company

Fineline Cube Jun 30, 2026
Company Deals

Eli Lilly Partners with Innovent Biologics on Verzenio CDK4/6 Inhibitor – Chinese Biotech Secures Exclusive Commercialization Rights in Mainland China

Fineline Cube Jun 30, 2026
Company Deals

Qyuns Therapeutics to Acquire Remaining 34% Stake in CMC Subsidiary Cellularforce for RMB 86M – Full Ownership Secures NDA Pathway for IL-17A and IL-4Rα Antibody Pipeline

Fineline Cube Jun 30, 2026
Policy / Regulatory

China’s CDE Unveils 108th Batch of Reference Preparations for Generic Drug Evaluation, Adds 28 New Drugs

Fineline Cube Jun 29, 2026
Company Drug

Hybio Pharma’s Generic Tirzepatide ANDA Accepted by FDA – First-to-File Challenger Targets $20B+ Dual GLP-1/GIP Agonist Franchise with Paragraph IV Certification

Fineline Cube Jul 1, 2026
Company Drug

Roche Receives FDA Priority Review for Enspryng in Thyroid Eye Disease – IL-6 Inhibitor Leverages Novel Recycling Technology for Second Indication

Fineline Cube Jul 1, 2026
Company Drug

Evopoint Biosciences Submits Pre-NDA for Funobactam, Imipenem, and Cilastatin to NMPA

Fineline Cube Dec 18, 2024

Suzhou-based Evopoint Biosciences Co., Ltd. has announced the submission of a Pre-NDA (New Drug Application)...

Company Deals

Xtalpi Inc. Partners with Gnosis Neurodynamics to Develop Neural Drug Screening Platform

Fineline Cube Dec 18, 2024

Shenzhen-based QuantumPharm Inc., trading as Xtalpi Inc. (HKG: 2228), has announced a strategic partnership with...

Company Drug

GSK’s Blenrep and Star Pharma’s Topiramate Solution Target Priority Review in China

Fineline Cube Dec 18, 2024

The China’s Center for Drug Evaluation (CDE) website has signaled that GlaxoSmithKline’s (GSK; NYSE: GSK)...

Company Drug

Sciwind Biosciences’ Ecnoglutide Accepted for Review by NMPA for Weight Management

Fineline Cube Dec 18, 2024

Sciwind Biosciences Co., Ltd has received a significant boost as the National Medical Products Administration...

Company Deals

Blackstone and Bain Capital Submit Final Bids for Mitsubishi Tanabe Pharma

Fineline Cube Dec 18, 2024

In a significant development in the alternative asset management sector, companies such as Blackstone and...

Company Drug

Everest Medicines’ Velsipity NDA for Ulcerative Colitis Accepted by China’s NMPA

Fineline Cube Dec 17, 2024

China-based Everest Medicines (HKG: 1952) has announced that the National Medical Products Administration (NMPA) has...

Drug

AstraZeneca’s ALXN2350 Selected for CDE’s Rare Disease Drug Development Program

Fineline Cube Dec 17, 2024

The Center for Drug Evaluation (CDE) in China has announced its intention to include AstraZeneca’s...

Policy / Regulatory

NMPA’s CDE Releases Draft Proposal for Benefit-Risk Assessment in Global Drug Development

Fineline Cube Dec 17, 2024

The Center for Drug Evaluation of the National Medical Products Administration (NMPA) has issued the...

Hospital

Perennial Real Estate Holdings’ Tianjin Hospital Earns Medical Practice License

Fineline Cube Dec 17, 2024

Singapore-based Perennial Real Estate Holdings Limited has announced that its Perennial General Hospital in Tianjin...

Company Drug

MSD Halts Development of Vibostolimab and Favezelimab Due to Trial Setbacks

Fineline Cube Dec 17, 2024

US pharmaceutical giant Merck, Sharp & Dohme (MSD; NYSE: MRK) has revealed its decision to...

Company Deals

Adcendo ApS Expands Partnership with Biocytogen to Enhance ADC Pipeline

Fineline Cube Dec 17, 2024

China’s Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (HKG: 2315) has announced that Denmark-based Adcendo ApS has...

Company Medical Device

MicroPort CardioFlow’s VitaFlow Liberty Receives Marketing Approval in Turkey

Fineline Cube Dec 17, 2024

China-based MicroPort CardioFlow Medtech Co., Ltd (HKG: 2160) has announced that its second-generation transcatheter aortic...

Company Drug

Vcanbio’s VUM02 Secures NMPA Approval and FDA ODD for Cirrhosis and aGvHD

Fineline Cube Dec 17, 2024

China-based Vcanbio Cell & Gene Engineering Corp., Ltd (SHA: 600645) has announced significant progress for...

Company

Novo Nordisk Invests DKK 8.5 Billion in New Odense Manufacturing Facility

Fineline Cube Dec 17, 2024

Denmark-based pharmaceutical giant Novo Nordisk A/S (NYSE: NVO) is making a significant investment in its...

Company Drug

Johnson & Johnson Submits sBLA to FDA for Simponi in Pediatric Ulcerative Colitis

Fineline Cube Dec 17, 2024

US pharmaceutical major Johnson & Johnson (J&J, NYSE: JNJ) has announced the submission of a...

Company Drug

J&J’s SC Amivantamab Faces Complete Response Letter from FDA for NSCLC Treatment

Fineline Cube Dec 17, 2024

Johnson & Johnson (J&J, NYSE: JNJ) has announced that the Biologics License Application (BLA) filed...

Company Drug

Grand Pharmaceutical’s GPN01768 Accepted for Review by NMPA for Demodex Blepharitis Treatment

Fineline Cube Dec 17, 2024

Grand Pharmaceutical Group Co., Ltd. (HKG: 0512) has announced that the National Medical Products Administration...

Company Drug

Jiangsu Hengrui’s Trastuzumab Rezetecan on Track for NMPA’s Breakthrough Therapy Designation

Fineline Cube Dec 17, 2024

Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276), a leading pharmaceutical company based in China, has...

Company Drug

Abbisko Therapeutics Receives NMPA Approval for Irpagratinib Regulatory Study

Fineline Cube Dec 17, 2024

Shanghai-based biotech Abbisko Therapeutics Co., Ltd (HKG: 2256) has announced that it has received approval...

Company Drug

Vocabria Receives Positive CHMP Opinion for HIV Treatment in Adolescents

Fineline Cube Dec 17, 2024

GSK plc (NYSE: GSK) has announced that ViiV Healthcare, an HIV specialist majority owned by...

Posts pagination

1 … 267 268 269 … 689

Recent updates

  • Hybio Pharma’s Generic Tirzepatide ANDA Accepted by FDA – First-to-File Challenger Targets $20B+ Dual GLP-1/GIP Agonist Franchise with Paragraph IV Certification
  • Roche Receives FDA Priority Review for Enspryng in Thyroid Eye Disease – IL-6 Inhibitor Leverages Novel Recycling Technology for Second Indication
  • Huiyu Pharma Receives NMPA Clinical Trial Approval for HY-1016 Extended-Release Dienogest Injection – Novel Formulation Aims to Transform Endometriosis Treatment Adherence
  • RaysightMed Secures Nearly RMB 100 Million in Strategic Financing Led by State-Owned Capital – Accelerates Cardiovascular Diagnostics Scale-Up and AI Surgical Robotics Development
  • CSPC Innovation Launches Phase III Trial of SYS6010 ADC-PD-1 Combo in Resected NSCLC – Novel EGFR-Targeted Antibody-Drug Conjugate Enters Adjuvant Setting
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Hybio Pharma’s Generic Tirzepatide ANDA Accepted by FDA – First-to-File Challenger Targets $20B+ Dual GLP-1/GIP Agonist Franchise with Paragraph IV Certification

Company Drug

Roche Receives FDA Priority Review for Enspryng in Thyroid Eye Disease – IL-6 Inhibitor Leverages Novel Recycling Technology for Second Indication

Company Drug

Huiyu Pharma Receives NMPA Clinical Trial Approval for HY-1016 Extended-Release Dienogest Injection – Novel Formulation Aims to Transform Endometriosis Treatment Adherence

Company Deals

RaysightMed Secures Nearly RMB 100 Million in Strategic Financing Led by State-Owned Capital – Accelerates Cardiovascular Diagnostics Scale-Up and AI Surgical Robotics Development

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.